Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer

Inclusion Criteria: * Newly diagnosed with advanced NSCLC (stage IV a-c) that are wild-type for activating genetic alterations (EGFR, ROS 1, and ALK). * May or may not be candidates for immune checkpoint therapy. * May have had 1-any number of prior systemic therapy regimens. * If prior systemic regimen, must have progression disease at time of evaluation. * Untreated brain metastases permitted. * Completed pathological analysis of tumor tissue. * Patients who have exhausted targeting therapy options. * Can speak and read English. * All participants must be willing to comply with all study procedures and be available for the duration of the study. * Providers: Those who treat NSCLC patients as described above. Exclusion Criteria: • There are no specific exclusions in this trial for particular medical conditions, comorbidities, or performance status. Any patient deemed appropriate to be considered for evaluation and/or treatment would be appropriate to include in this trial.